Chief Business Officer · G1 Therapeutics, Inc. (GTHX)

Mark Avagliano

A named executive officer of G1 Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,171,543

Salary $483,604Stock awards $338,276

FY2022: $1,137,024

2nd of 3 named executive officers at G1 Therapeutics by FY2023 total.

3 named officers on file for G1 Therapeutics, FY2023

Mark Avagliano’s pay file — $29

  • 2 fiscal years of pay, line by line
  • GTHX’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how G1 Therapeutics’s whole pay program stands against its peers

  • G1 Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on GTHX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Mark Avagliano’s full pay file as a PDF — free

More than this page: up to 10 years of Mark’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Mark Avagliano compensation by year

G1 Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as G1 Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$465,005$483,604
Bonus$0$0
Stock awards$128,280$338,276
Option awards$380,207$169,533
Non-equity incentive$154,382$170,229
Pension and deferred compensation$0$0
All other$9,150$9,900
Total$1,137,024$1,171,543

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: G1 Therapeutics, Inc. DEF 14A filed April 25, 2024, accession 0001193125-24-113902, and prior-year filings. Open the filing on EDGAR.

How this page was built: the G1 Therapeutics, Inc. filed document, accession 0001193125-24-113902. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2024.

$1.1M
$1.2M
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU35,000$106,750—
RSU20,600$62,830—
PSU20,600$62,830—
RSU7,500$22,875—
RSU4,125$12,581—
Option27,606—$10.69
Option2,500—$21.08
Option15,716—$18.07
Option41,100—$5.73

Per the Outstanding Equity Awards at Fiscal Year-End table in G1 Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

8 Form 4 lines since the FY2023 proxy (filed April 25, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-09-18Grant or award—20,600—262,645
2024-09-18Disposition to the issuer derivative—89,400—0
2024-09-18Disposition to the issuer derivative—41,100—0
2024-09-18Disposition to the issuer—236,610—26,035
2024-09-18U—26,035—0
2024-07-05Sale—2,638$2.51242,045
2024-07-01Grant or award—35,000$0.00244,683
2024-05-13Sale—8,151$4.79209,683

The 8 most recent of 8 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments G1 Therapeutics discloses, by trigger · FY2023
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Death$0$0—$0
Involuntary for cause$0$0—$0
Resignation for good reason, no change in control$483,605$17,728—$501,333
Change in control and involuntary termination$483,605$267,866—$751,471
Change in control and resignation for good reason$483,605$267,866—$751,471
Voluntary resignation$0$0—$0
Involuntary termination without cause$483,605$17,728—$501,333
Change in control, no termination—$267,866—$267,866
Disability$0$0—$0

Per the Potential Payments Upon Termination or Change in Control table in G1 Therapeutics, Inc.'s FY2023 proxy. Estimates as the company printed them; a dash means it printed no figure.

G1 Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
John BaileyChief Executive Officer and President$3,250,658
Mark Avagliano · this pageChief Business Officer$1,171,543
Rajesh MalikChief Medical Officer$1,108,156

The full G1 Therapeutics compensation record

free company brief

This page is one person within G1 Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are G1 Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Avagliano's compensation dossier · One-time report. No refunds.